- Home
- CNTA vs TSLX Comparison
CNTA vs TSLX Comparison
Compare CNTA & TSLX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- CNTA
- TSLX
- Stock Information
- Founded
- CNTA 2020
- TSLX 2010
- Country
- CNTA United Kingdom
- TSLX United States
- Employees
- CNTA N/A
- TSLX N/A
- Industry
- CNTA Biotechnology: Pharmaceutical Preparations
- TSLX Investment Managers
- Sector
- CNTA Health Care
- TSLX Finance
- Exchange
- CNTA Nasdaq
- TSLX Nasdaq
- Market Cap
- CNTA 2.2B
- TSLX 1.9B
- IPO Year
- CNTA 2021
- TSLX 2014
- Fundamental
- Price
- CNTA $18.19
- TSLX $20.56
- Analyst Decision
- CNTA Strong Buy
- TSLX Strong Buy
- Analyst Count
- CNTA 7
- TSLX 7
- Target Price
- CNTA $23.71
- TSLX $22.07
- AVG Volume (30 Days)
- CNTA 527.9K
- TSLX 386.8K
- Earning Date
- CNTA 11-12-2024
- TSLX 11-05-2024
- Dividend Yield
- CNTA N/A
- TSLX 11.51%
- EPS Growth
- CNTA N/A
- TSLX N/A
- EPS
- CNTA N/A
- TSLX 2.06
- Revenue
- CNTA $6,853,000.00
- TSLX $478,363,000.00
- Revenue This Year
- CNTA N/A
- TSLX $10.92
- Revenue Next Year
- CNTA N/A
- TSLX N/A
- P/E Ratio
- CNTA N/A
- TSLX $9.98
- Revenue Growth
- CNTA N/A
- TSLX 14.25
- 52 Week Low
- CNTA $5.58
- TSLX $19.50
- 52 Week High
- CNTA $18.74
- TSLX $22.35
- Technical
- Relative Strength Index (RSI)
- CNTA 64.61
- TSLX 53.70
- Support Level
- CNTA $15.00
- TSLX $20.36
- Resistance Level
- CNTA $18.74
- TSLX $20.55
- Average True Range (ATR)
- CNTA 1.18
- TSLX 0.32
- MACD
- CNTA 0.10
- TSLX 0.04
- Stochastic Oscillator
- CNTA 85.29
- TSLX 90.86
About CNTA Centessa Pharmaceuticals plc
Centessa Pharmaceuticals PLC is a clinical-stage pharmaceutical company. The company's pipeline assets include 1) SerpinPC for Hemophilia A, B, 2) LB101 for Solid Tumors, 3) ORX750 for Narcolepsy Type 1 (NT1) and other sleep disorders, 4) MGX292 Pulmonary Arterial Hypertension (PAH) and 5) Undisclosed for Solid Tumors.
About TSLX Sixth Street Specialty Lending Inc.
Sixth Street Specialty Lending Inc is a specialty finance company focused on providing flexible, fully committed financing solutions to middle market companies located in the United States of America. It partners with companies across a variety of industries and excel at providing creative solutions to companies with complex business models that may have limited access to capital. The company seeks to generate current income in U.S.-domiciled middle-market companies through direct originations of senior secured loans and, to a lesser extent, originations of mezzanine and unsecured loans and investments in corporate bonds and equity securities.